TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01018745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-907351 (XL184)
Description: Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
Study: NCT04686708

Intervention type: OTHER
Intervention: Emergency general surgical admissions
Description: All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).

Intervention type: OTHER
Intervention: Emergency general surgical admissions
Description: All emergency general surgical admissions are admitted initially to the emergency department and then referred to the general surgery department for further management (medical, interventional, or surgical approaches).
Study: NCT01236625

Intervention type: PROCEDURE
Intervention: Adhesiolysis
Description: Blunt or sharp dissection of adhesive tissue.
Study: NCT01973517

Intervention type: DRUG
Intervention: Feraheme
Description: Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.

Intervention type: DRUG
Intervention: Gadolinium-based contrast
Description: Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
Study: NCT06178042

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Description: Briefly, a pea-sized amount of the cream was used once a day and was allowed to remain on the teeth for three minutes after conventional tooth brushing. Patient was advised to not to spit out the cream for 30 seconds to activate the product with saliva. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: The cream must remain on the teeth for at least three minutes once daily after conventional tooth brushing. Patient was advised to spit out the remaining amount to avoid swallowing excessive fluoride and to wait for 30 minutes after the treatment before rinsing or eating or drinking.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients instructed to follow a routine home care.
Study: NCT03625700

Intervention type: DRUG
Intervention: Oxygen gas
Description: Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.

Intervention type: DRUG
Intervention: Oxygen gas
Description: Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.

Intervention type: DRUG
Intervention: Oxygen gas
Description: Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
Study: NCT03222453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoetic stem cells
Description: Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
Study: NCT02212925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 14332 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03499106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Capsule
Study: NCT00765739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: voluntary strengthening exercise
Description: contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
Study: NCT03543176

Intervention type: OTHER
Intervention: UMEC/VI
Description: UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .

Intervention type: OTHER
Intervention: FLUT/SAL
Description: FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.

Intervention type: OTHER
Intervention: CAT
Description: Questionnaire used to asses Condition-related well-being, for COPD subjects.

Intervention type: OTHER
Intervention: CAT
Description: Questionnaire used to asses Condition-related well-being, for COPD subjects.

Intervention type: OTHER
Intervention: mMRC
Description: Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.

Intervention type: OTHER
Intervention: mMRC
Description: Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.

Intervention type: DEVICE
Intervention: Ellipta
Description: It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.

Intervention type: DEVICE
Intervention: Diskus
Description: It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
Study: NCT03911076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVX-2
Description: pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBS and PGC
Study: NCT04464746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implementation of a specific program to improve therapeutic adherence
Description: 1. Discussion of risks associated with high BP;aims,healthy lifestyle options.~2. Individualized educational intervention:verbal, written,audiovisual information. Evaluation of knowledge of prescribed drugs.~3. Behavioral counseling.training patients to participate in their own care, while positively modifying their skills or routines (i.e. pill boxes,calendars,specific measures to remind the patient taking drugs,adapt the regimen to atient's daily routine).~4. Socio-psycho-affective interventions.~5. Reminder systems: phone,email,alarm on the mobile phone.~6. Simplification as far as possible of therapeutic scheme.~7. Explanation of prescribed medications (name\&dosage), correct intake.~8. Explanation of possible side effects and what to do if they happen. Facilitate a contact.~9. Advise and training on home blood pressure self-measurement.~10. Verbal, written and/or audiovisual information and the online patients'section of scientific societies addresses will be provided.
Study: NCT03308604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polysiloxane Gd-Chelates based nanoparticles (AGuIX)
Description: Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later.~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/kg (level 2). The starting dose level will be 30mg/kg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Description: to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Uterovaginal brachytherapy
Description: 15 Gy (maximal interval between EBRT and brachytherapy: 14 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin)
Description: Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
Study: NCT00134966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
Study: NCT03835507

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: recombinant human erythropoietin(rhEPO)
Description: Injection of erythropoietin every months (total 12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin(rhEPO)
Description: Injection of erythropoietin every months (total 12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin(rhEPO)
Description: Injection of erythropoietin every months (total 12 months)
Study: NCT01466075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Evolution Investigational BG Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
Study: NCT00391872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor (AZD6140) 90 mg twice daily dose (BD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily dose (ODD)
Study: NCT02484092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPK-9001
Description: A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
Study: NCT00215644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matuzumab
Description: Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.
Study: NCT03089645

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5083 monotherapy
Description: Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEID5083 with Durvalumab or Tremelimumab
Description: Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medi5083 with Durvalumab and Docetaxel
Description: Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
Study: NCT03370965

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuro-ophtalmology examination
Description: Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment.
Study: NCT03701438

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: Administered per standard of care using a vaccine licensed and recommended in the site's country
Study: NCT00447551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-L-Lactic Acid
Description: Deep dermal injection
Study: NCT03559751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLN cigarettes (A)
Description: 0.4mg nicotine / g tobacco king size filter cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarettes (B)
Description: Usual brand king size non-menthol cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Brand Cigarettes (B)
Description: Usual brand king size non-menthol cigarettes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum (C)
Description: 4 mg nicotine gum
Study: NCT03746405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: excitatory 5Hz rTMS will be used

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
Study: NCT00540839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast 4 mg OG or montelukast 4 mg CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to montelukast
Description: Placebo OG or CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone 50 mcg inhalation aerosol metered dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to fluticasone
Description: Placebo inhalation aerosol metered dose inhaler
Study: NCT02793219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT02778035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dorsomedial prefrontal rTMS
Description: Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
Study: NCT03063619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimoxifene
Description: Applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied topically

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00308516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: radiation 1.8 Gy/day or 28 fractions weeks 1-6

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: radiation 1.8 Gy/day or 28 fractions weeks 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15
Study: NCT03290118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Traffic Light
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Health Star
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Rating System - Warning Label
Description: Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application FoodFlip Device®
Description: This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application FoodFlip Device®
Description: This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application FoodFlip Device®
Description: This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
Study: NCT03787602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
Study: NCT02065401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (disodium salt, granule)
Description: Single oral dose of 1500 mg administered on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferitazole (disodium salt, tablet)
Description: Single oral dose of 1500 mg administered on Day 1